Literature DB >> 7834178

Mutations in transmembrane segment VII of the AT1 receptor differentiate between closely related insurmountable and competitive angiotensin antagonists.

H T Schambye1, B von Wijk, S A Hjorth, W Wienen, M Entzeroth, D J Bergsma, T W Schwartz.   

Abstract

Chimeric constructs between the human and the Xenopus laevis AT1 receptor have demonstrated, that the binding of non-peptide angiotensin antagonists is dependent on non-conserved residues located deep in transmembrane segment VII of the AT1 receptor. Here we have studied four pairs of closely related antagonists each consisting of a competitive and an insurmountable compound differentiated by one out of three different types of minor chemical modifications. None of the antagonists bound to the Xenopus receptor and the binding of all of the compounds to the human receptor was severely impaired by the introduction of non-conserved residues from transmembrane segment VII of the Xenopus receptor. In all four pairs of antagonists the competitive compound was affected more by these substitutions than the corresponding insurmountable one (209 vs. 22, 281 vs. 29, 290 vs. 29 and 992 vs. 325-fold increase in Ki values). A similar pattern was observed in response to substitution of a single non-conserved residue in transmembrane segment VII, Asn295 to Ser. These results indicate that a common molecular mechanism distinguishes the interaction of insurmountable and competitive antagonists with the AT1 receptor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7834178      PMCID: PMC1510146          DOI: 10.1111/j.1476-5381.1994.tb16899.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  5 in total

1.  Cloning and characterization of a human angiotensin II type 1 receptor.

Authors:  D J Bergsma; C Ellis; C Kumar; P Nuthulaganti; H Kersten; N Elshourbagy; E Griffin; J M Stadel; N Aiyar
Journal:  Biochem Biophys Res Commun       Date:  1992-03-31       Impact factor: 3.575

2.  Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies.

Authors:  W Wienen; A B Mauz; J C Van Meel; M Entzeroth
Journal:  Mol Pharmacol       Date:  1992-06       Impact factor: 4.436

3.  Chimeric NK1 (substance P)/NK3 (neurokinin B) receptors. Identification of domains determining the binding specificity of tachykinin agonists.

Authors:  U Gether; T E Johansen; T W Schwartz
Journal:  J Biol Chem       Date:  1993-04-15       Impact factor: 5.157

4.  Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277.

Authors:  W Wienen; N Hauel; J C Van Meel; B Narr; U Ries; M Entzeroth
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

5.  Isolation and expression of a novel angiotensin II receptor from Xenopus laevis heart.

Authors:  D J Bergsma; C Ellis; P R Nuthulaganti; P Nambi; K Scaife; C Kumar; N Aiyar
Journal:  Mol Pharmacol       Date:  1993-08       Impact factor: 4.436

  5 in total
  2 in total

1.  GPCR-I-TASSER: A Hybrid Approach to G Protein-Coupled Receptor Structure Modeling and the Application to the Human Genome.

Authors:  Jian Zhang; Jianyi Yang; Richard Jang; Yang Zhang
Journal:  Structure       Date:  2015-07-16       Impact factor: 5.006

2.  Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.

Authors:  M T Le; M K Pugsley; G Vauquelin; I Van Liefde
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.